

## **KINAXO enters into agreement with Schering AG on kinase inhibitor profiling**

*Martinsried, July 27, 2006.* KINAXO Biotechnologies GmbH announced today that it has entered into a services and collaboration agreement with Schering AG, Germany (FSE: SCH, NYSE: SHR). Under the agreement, KINAXO will employ the KinaTor™ technology to perform selectivity analyses for Schering AG's small molecule kinase inhibitors. The results of this study will support Schering AG's lead optimization activities in the field of kinase inhibitors.

"We are delighted to enter into this collaboration with Schering AG. It underlines the benefits of our technology platform for developing the next generation of kinase inhibitors," said Dr. Andreas Jenne, CEO of KINAXO. "The KinaTor™ technology permits rational decisions based on proteome-wide selectivity data and greatly facilitates the development of clean and spectrum-selective kinase drugs with well-characterized inhibition profiles."

### **About KinaTor™**

The KinaTor™ technology uses immobilized kinase inhibitors to detect their protein binding partners in cell lines or tissue samples. Sophisticated affinity-based separation procedures in combination with sensitive mass spectrometry and biochemical assays allow us to reliably identify and quantify the protein-small molecule interactions of kinase inhibitors. The technology can be easily adapted to a vast range of small molecule compounds, providing tailor-made solutions for numerous applications, including the (i) identification of previously unknown disease-relevant targets; (ii) identification of potential compound-related toxicities due to off-target effects; (iii) development of spectrum-specific kinase inhibitors; (iv) assessment of a drug's therapeutic potential in other medical indications; (v) development of new applications for "stalled" compounds; or (vi) target identification and mode of action determination for compounds found in cell-based drug screening.

### **About KINAXO**

KINAXO Biotechnologies GmbH, a spin-off from the Max Planck Institute of Biochemistry in Martinsried, is a privately-held biotechnology company based in Munich/Martinsried, Germany. We support pharmaceutical and biotechnology companies in the development and optimization of selective kinase inhibitors. KINAXO offers a comprehensive chemical-proteomics technology - known as KinaTor™ - to identify and characterize the interaction of kinase inhibitors with their protein targets in the physiological context of a cell. Tailored to protein kinases, the KinaTor™ technology represents a highly efficient approach to developing selective kinase inhibitors and significantly enhances directed optimization of novel drug leads.

### **Contact**

Dr. Andreas Jenne, CEO  
KINAXO Biotechnologies GmbH  
Am Klopferspitz 19a  
82152 Martinsried, Germany  
[www.kinaxo.com](http://www.kinaxo.com)

Phone: +49 172 87 10 562  
Email: [info@kinaxo.de](mailto:info@kinaxo.de)